AstraZeneca’s Imfinzi significantly improves OS in phase III SCLC trial

This article was originally published here

Imfinzi, along with four cycles of standard-of-care (SoC) chemotherapy, showed a statistically-significant and clinically-meaningful improvement in OS against SoC including up to six cycles of chemotherapy and optional

The post AstraZeneca’s Imfinzi significantly improves OS in phase III SCLC trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply